NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
Q-Line Biotech

Q-Line Biotech

Open Date

May 21, 2026

Close Date

May 25, 2026

listed

Min Investment

₹2,74,400

Lot Size

400 Shares

Issue Size

₹214.48 Cr

Price Range

₹326 - ₹326

Listing Date

May 29, 2026

IPO Doc

RHP PDF

About Q-Line Biotech

Founded in 2010, Q-Line Biotech Ltd. is involved in the development, manufacture and commercialization of various reagents (kits and POC devices) and consumables and manufacturing, importation, and supply of diagnostic instruments for different healthcare requirements. Q-Line Biotech Ltd. has been providing diagnostic instruments and IVD products for different healthcare requirements since 2013 either directly or via our distributor(s) primarily to diagnostic service organizations, hospitals, and medical colleges. Q-Line Biotech Ltd.'s manufacturing categories comprise indigenous manufacture of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others (POC Devices & Rapid Tests) and supply/ manufacture of in vitro diagnostics (IVD), pathology equipment and devices. As of March 31, 2025, the company employed 313 permanent employees.

Checklist Quality Analysis

Revenue Growth

Company Valuation

Earning Expansion

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.

0GMP

Q-Line Biotech IPO - Issue Objectives

The company will utilise ₹93.50 crore for working capital requirement of the business. The company will use ₹90 crore for repayment of borrowings. Part of the IPO proceeds will be used for general corporate purposes and issue expenses

Working capital expenditure

43.6%

Repayment of borrowings

42.06%

General corporate purposes

14.25%

1

Working capital expenditure

The company will utilise ₹93.50 crore for working capital requirement of the business.

43.60%
2

Repayment of borrowings

The company will use ₹90 crore for repayment of borrowings.

42.06%
3

General corporate purposes

Part of the IPO proceeds will be used for general corporate purposes and issue expenses

14.25%

IPO Subscription Status

Retails
70.92x
QIB
123.94x
NII
438.82x

Financials of Q-Line Biotech

In Cr.

Contact Details

Q-Line Biotech

298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh - 226012.

Q-Line Biotech IPO - FAQs

Q-Line Biotech IPO is a SME IPO. The issue is priced at 326-₹343. The minimum order quantity is 400 Shares. The IPO opens on 21 May, and closes on 25 May. TBA is the registrar for the IPO. The shares are proposed to be listed on SME.

Live IPOs

CMR Green Technologies logo

CMR Green Technologies

Mainboard
BSE
NSE
Open  Close3rd Jun 2026 - 5th Jun 2026
Issue Size630.88 Cr
Min. Qty78 Shares
Issue Price₹ 182.00
Live IPO
Vahh Chemicals logo

Vahh Chemicals

SME
Open  Close4th Jun 2026 - 8th Jun 2026
Issue Size13.45 Cr
Min. Qty2000 Shares
Issue Price₹ 60.00
Live IPO
UHM Vacation logo

UHM Vacation

SME
Open  Close4th Jun 2026 - 8th Jun 2026
Issue Size36.02 Cr
Min. Qty800 Shares
Issue Price₹ 166.00
Live IPO
Hexagon Nutrition logo

Hexagon Nutrition

Mainboard
Open  Close5th Jun 2026 - 9th Jun 2026
Issue Size138.87 Cr
Min. Qty333 Shares
Issue Price₹ 42.00
Live IPO
See All Live IPOs
IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.